Comparative Pharmacology
Head-to-head clinical analysis: BROMFENAC SODIUM versus OCUFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMFENAC SODIUM versus OCUFEN.
BROMFENAC SODIUM vs OCUFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis, leading to decreased inflammation, pain, and fever. Specifically, bromfenac is a potent inhibitor of COX-2.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, thereby decreasing intraocular inflammation and pain.
One drop (0.1 mL) of 0.09% ophthalmic solution (bromfenac 0.9 mg/mL) instilled into the affected eye(s) twice daily beginning 24 hours before cataract surgery and continuing on the day of surgery and for 14 days postoperatively.
1 drop of 0.03% solution in the affected eye(s) four times daily beginning 24 hours after cataract surgery.
None Documented
None Documented
Terminal elimination half-life: 1.5-2.5 hours (prolonged in renal impairment; clinical context: short half-life supports twice-daily dosing in ophthalmic use)
1.2 to 2.0 hours (topical administration in ocular tissues); systemic half-life is 1.1 to 1.4 hours.
Renal: ~80% (primarily as unchanged drug and glucuronide conjugate); Biliary/Fecal: ~20%
Urinary excretion of unchanged drug accounts for approximately 82% of a topical dose; fecal excretion is minor (<5%).
Category C
Category C
Ophthalmic NSAID
Ophthalmic NSAID